{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:27:09Z","timestamp":1793608029092,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Quebec Health Research Fund","doi-asserted-by":"publisher","award":["30641"],"award-info":[{"award-number":["30641"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013392","name":"Quebec Ministry of Health and Social Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129107","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:18:12Z","timestamp":1788455892000},"page":"129107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Follow up immunogenicity of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccines 36\u00a0months post-vaccination among boys and girls"],"prefix":"10.1016","volume":"92","author":[{"given":"Iulia Gabriela","family":"Ionescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manale","family":"Ouakki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Breton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitika","family":"Panicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Gilca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Sauvageau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129107_bb0005","author":"Minist\u00e8re de la Sant\u00e9 et des Services sociaux"},{"key":"10.1016\/j.vaccine.2026.129107_bb0010","author":"Minist\u00e8re de la Sant\u00e9 et des Services sociaux"},{"key":"10.1016\/j.vaccine.2026.129107_bb0015","author":"Merck Canada Inc"},{"key":"10.1016\/j.vaccine.2026.129107_bb0020","author":"GlaxoSmithKline Inc"},{"key":"10.1016\/j.vaccine.2026.129107_bb0025","author":"Comit\u00e9 sur l'\u2019immunisation du Qu\u00e9bec"},{"key":"10.1016\/j.vaccine.2026.129107_bb0030","author":"Minist\u00e8re de la Sant\u00e9 et des Services sociaux"},{"issue":"46","key":"10.1016\/j.vaccine.2026.129107_bb0035","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1016\/j.vaccine.2018.09.057","article-title":"Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - a randomized clinical trial","volume":"36","author":"Gilca","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129107_bb0040","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/21645515.2015.1011570","article-title":"The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine","volume":"11","author":"Gilca","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"issue":"2","key":"10.1016\/j.vaccine.2026.129107_bb0045","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/21645515.2018.1522469","article-title":"Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later \u2013 an exploratory study","volume":"15","author":"Gilca","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.129107_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127475","article-title":"Immune response after one dose of HPV vaccine among girls and boys and the impact of a second dose given after 3 or more years","volume":"62","author":"Guzun","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129107_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127893","article-title":"Long term immunogenicity of two doses of the quadrivalent HPV vaccine and the effect of an additional dose given five years post-primary vaccination","volume":"68","author":"Sauvageau","year":"2025","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129107_bb0060","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/cid\/ciw865","article-title":"Sustained antibody responses 6 years following 1, 2, or 3 doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: a prospective cohort study","volume":"64","author":"Toh","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.129107_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1327770","article-title":"Immune response following a two-dose schedule of bivalent HPV vaccination among girls and boys","volume":"15","author":"Middeldorp","year":"2024","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.vaccine.2026.129107_bb0070","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev. Res. (Phila.)"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129107_bb0075","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.vaccine.2026.129107_bb0080","doi-asserted-by":"crossref","first-page":"e1473","DOI":"10.1016\/S2214-109X(22)00309-6","article-title":"Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial","volume":"10","author":"Watson-Jones","year":"2022","journal-title":"Lancet Glob. Health"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129107_bb0085","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.4161\/hv.29617","article-title":"Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9\u201310 year-old girls according to 0\u20136 month schedule","volume":"10","author":"Gilca","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"12","key":"10.1016\/j.vaccine.2026.129107_bb0090","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S1473-3099(25)00284-1","volume":"25","author":"Cort\u00e9s","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.129107_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2021.113136","article-title":"Multiplex immunoassay to measure antibody response to nine HPV vaccine types","volume":"498","author":"Panicker","year":"2021","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.vaccine.2026.129107_bb0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jim.2014.12.013","article-title":"Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types","volume":"417","author":"Panicker","year":"2015","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129107_bb0105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41541-024-00949-2","article-title":"WHO international standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58","volume":"9","author":"Kemp","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129107_bb0110","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2214-109X(24)00477-7","article-title":"Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9\u201314 years: results of the long-term extension of the DoRIS randomised trial","volume":"13","author":"Watson-Jones","year":"2025","journal-title":"Lancet Glob. Health"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129107_bb0115","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.vaccine.2022.11.044","article-title":"Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination","volume":"41","author":"Joshi","year":"2023","journal-title":"Vaccine"},{"issue":"67","key":"10.1016\/j.vaccine.2026.129107_bb0120","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jncimonographs\/lgae032","article-title":"HPV16\/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial","volume":"2024","author":"Porras","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"67","key":"10.1016\/j.vaccine.2026.129107_bb0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jncimonographs\/lgae042","article-title":"A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination","volume":"2024","author":"Malvi","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"24","key":"10.1016\/j.vaccine.2026.129107_bb0130","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1056\/NEJMoa2506765","article-title":"Noninferiority of one HPV vaccine dose to two doses","volume":"393","author":"Kreimer","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.vaccine.2026.129107_bb0135","first-page":"1","article-title":"HPV-specific systemic antibody responses and memory B cells are independently maintained up to 6 years and in a vaccine-specific manner following immunization with Cervarix and Gardasil in adolescent and young adult women in vaccination programs in Italy","volume":"8","author":"Nicoli","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.129107_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2026.101401","article-title":"Exceeding expectations: factors contributing to the potency of human papillomavirus vaccines","author":"Schiller","year":"2026","journal-title":"Lancet Microbe"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129107_bb0145","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-026-01408-w","article-title":"Plasmablast, memory B cell and T follicular helper cell responses after human papillomavirus vaccination: effect of dose number and age","volume":"11","author":"Kiamba","year":"2026","journal-title":"Npj Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129107_bb0150","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2425146","article-title":"Immunogenicity of the 9-valent human papillomavirus vaccine: post hoc analysis from five phase 3 studies","volume":"21","author":"Giuliano","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.vaccine.2026.129107_bb0155","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-060301","article-title":"HPV16\/18 antibody responses after a single dose of nonavalent HPV vaccine","volume":"152","author":"Zeng","year":"2023","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129107_bb0160","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-4035","article-title":"Three-year follow-up of 2-dose versus 3-dose HPV vaccine","volume":"147","author":"Bornstein","year":"2021","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.129107_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-72654-8","article-title":"Efficacy and durability of immediate versus delayed single-dose HPV vaccination for persistent infection among young women in Kenya: a randomized, blinded, cross-over clinical trial","author":"Barnabas","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vaccine.2026.129107_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.pvr.2019.100177","article-title":"Is one dose of human papillomavirus vaccine as effective as three?: a national cohort analysis","volume":"8","author":"Brotherton","year":"2019","journal-title":"Papillomavirus Research"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129107_bb0175","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum Vaccin"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129107_bb0180","first-page":"465","article-title":"AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix\u00ae): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types","volume":"71","author":"McKeage","year":"2011","journal-title":"Drugs"},{"issue":"48","key":"10.1016\/j.vaccine.2026.129107_bb0185","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12\u201326 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2026.129107_bb0190","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1080\/21645515.2019.1605278","article-title":"Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials","volume":"15","author":"Gilca","year":"2019","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:36:12Z","timestamp":1793604972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26009163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"alternative-id":["S0264410X26009163"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129107","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Follow up immunogenicity of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccines 36\u00a0months post-vaccination among boys and girls","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129107"}}